MORGAN STANLEY PLC/CALL/ASTRAZENECA ADR/75/0.1/20.06.25

MORGAN STANLEY PLC/CALL/ASTRAZENECA ADR/75/0.1/20.06.25 Share Price

DE000ME3JA32

Market Closed - Börse Stuttgart 17:44:47 28/06/2024 BST
0.98 ^EUR	+2.08%

Current month	+1.03%
1 month	+8.89%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart ASTRAZENECA PLC

Chart MORGAN STANLEY PLC/CALL/ASTRAZENECA ADR/75/0.1/20.06.25

Latest news about ASTRAZENECA PLC

Presage Biosciences Announces New Pharma Partnership to Evaluate Novel Immuno-Oncology Drug Combinations with CIVO® Technology	11-30	PR
New analysis of Phase II data at AACR assesses ImaginAb's investigational CD8 ImmunoPET technology's ability to predict response in immunotherapy	14/04/23	PR
Invitae Announces Partnership for Real-World Data Sharing to Inform Rare Cancer Research	27/10/22	PR
Baili Announces Clinical Trial Collaboration to Evaluate SI-B001, an EGFR x HER3 bispecific Antibody, in Combination with Tagrisso® in Patients with Non-Small Cell Lung Cancer	13/05/22	PR

More news

Quotes 5-day view

Date	Price	Change
28/06/24	0.98	+2.08%
27/06/24	0.96	-4.95%
26/06/24	1.01	-2.88%
25/06/24	1.04	+1.96%
24/06/24	1.02	+2.00%

Delayed Quote Börse Stuttgart

Last update June 28, 2024 at 05:44 pm

More quotes

Static data

Product type	Warrants
Buy / Sell	CALL
Underlying	ASTRAZENECA PLC
Issuer	Morgan Stanley
WKN	ME3JA3
ISIN	DE000ME3JA32
Date issued	13/11/2023
Strike	75 $
Maturity	20/06/2025 (357 Days)
Parity	10 : 1
Emission price	0.51 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	1.14 €
Lowest since issue	0.199 €
Delta	0.64x
Omega	4.872
Premium	9.28x
Gearing	7.63x
Moneyness	1.040
Difference Strike	-2.99 $
Difference Strike %	-3.99%
Spread	0.01 €
Spread %	1.04%
Theoretical value	0.9550
Implied Volatility	25.66 %
Total Loss Probability	44.29 %
Intrinsic value	0.2792
Present value	0.6758
Break even	85.23 €
Theta	-0.01x
Vega	0.03x
Rho	0.04x

Company Profile

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Sector

More about the company

Ratings for AstraZeneca PLC

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Consensus: AstraZeneca PLC

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

156.2 USD

Average target price

174.4 USD

Spread / Average Target

+11.69%

Consensus